Baxter International
BAX

$38.96

0.36%

Market Cap: $19.9B

About: Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.

Employees: 60,000

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0.04% less ownership

Funds ownership: 89.25% [Q1] → 89.21% (-0.04%) [Q2]

7% less funds holding

Funds holding: 913 [Q1] → 852 (-61) [Q2]

15% less repeat investments, than reductions

Existing positions increased: 270 | Existing positions reduced: 316

21% less capital invested

Capital invested by funds: $19.4B [Q1] → $15.2B (-$4.16B) [Q2]

22% less call options, than puts

Call options by funds: $90.7M | Put options by funds: $117M

36% less funds holding in top 10

Funds holding in top 10: 11 [Q1] → 7 (-4) [Q2]

39% less first-time investments, than exits

New positions opened: 95 | Existing positions closed: 156

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$30

23%

downside

Avg. target

$39

0%

upside

High target

$45

16%

upside

6 analyst ratings

1 positive

17%

4 neutral

67%

1 negative

17%

Goldman Sachs David Roman 50% 1-year accuracy 5 / 10 met price target	3%upside $40	Neutral Maintained	8 Aug 2024
JP Morgan Robbie Marcus 55% 1-year accuracy 11 / 20 met price target	8%upside $42	Neutral Maintained	7 Aug 2024
Wells Fargo Larry Biegelsen 68% 1-year accuracy 25 / 37 met price target	3%upside $40	Equal-Weight Maintained	7 Aug 2024
Morgan Stanley Patrick Wood 69% 1-year accuracy 9 / 13 met price target	23%downside $30	Underweight Downgraded	15 Jul 2024
Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target	5%downside $37	Neutral Maintained	10 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about BAX published over the past 30 days

Spectral Medical Provides August Tigris Trial Update

Management provides view on recently announced Vantive-Carlyle Group transaction Management provides view on recently announced Vantive-Carlyle Group transaction

Spectral Medical Provides August Tigris Trial Update

Baxter to Present at 2024 Wells Fargo Healthcare Conference

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Tuesday, March 4, 2025. About Baxter Every day, millions of patients and caregivers rely on Baxte.

Baxter to Present at 2024 Wells Fargo Healthcare Conference

Zacks Investment Research

Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average

From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average

Baxter To Sell Its Kidney Care Unit To Carlyle For $3.8 Billion

On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) announced that they have signed a definitive agreement under which Carlyle will acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion (For details refer to spinoffresearch.com). Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated to be approximately $3 billion.

Baxter To Sell Its Kidney Care Unit To Carlyle For $3.8 Billion

Zacks Investment Research

Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales

Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.

Baxter's (BAX) Vantive Divestiture to Aid Its Operational Sales

Zacks Investment Research

Why Baxter International (BAX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Baxter International (BAX) is a Top Value Stock for the Long-Term

Baxter Stock Falls After it Unloads Kidney Care Division in $3.8B Deal

Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash.

Baxter Stock Falls After it Unloads Kidney Care Division in $3.8B Deal

Investors Business Daily

Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More

Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion.

Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More

Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment

On Tuesday, Baxter International Inc BAX agreed to sell its Kidney Care segment, Vantive, for $3.8 billion to The Carlyle Group Inc CG

Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment

Baxter to sell its kidney care business in a $3.8 billion deal to Carlyle Group

Shares of Baxter International Inc. BAX, -0.59% tacked on 0.2% in premarket trading Tuesday, after the health care products company announced an agreement to sell its kidney care business to private equity investor Carlyle Group Inc. CG, -0.35% in a deal valued at $3.8 billion. Carlyle's stock was still untraded in the premarket.

Baxter to sell its kidney care business in a $3.8 billion deal to Carlyle Group

See News Rankings